Uncategorized
Nektar’s long-term mid-stage alopecia data fuels Phase 3 plans
Nektar Therapeutics’ data from the extension phase of a failed Phase 2b alopecia trial just about met Wall Street analyst expectations, helping the biotech’s ambitions to move forward in the indication.
The company’s rezpegaldesleukin, more …